Sanofi Venglustat Phase 3 Study Results for Type 3 Gaucher Disease

Explore the groundbreaking results of Sanofi's Venglustat in meeting all primary endpoints in a Phase 3 study focused on Type 3 Gaucher Disease. This video delves into the implications of this clinical trial for Pharma students, providing valuable insights into the treatment landscape for this rare genetic disorder.
Video Credit to -Ivan_Samkov.mp4

Видео Sanofi Venglustat Phase 3 Study Results for Type 3 Gaucher Disease канала MCQ Pedia